secwatch / observer
8-K filed January 20, 2023, 6:59 PM ET ticker XERS CIK 0001867096
other confidence medium sentiment neutral materiality 0.10

Xeris Biopharma amends credit deal to allow Letter of Financial Support to Australian unit

Xeris Biopharma Holdings, Inc.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Xeris Biopharma Holdings, Inc. amended Amendment No. 2 to Credit Agreement and Guaranty with Hayfin Services LLP, as administrative agent, and the lenders parties thereto (effective 2023-01-19).

Action
amendment
Agreement
credit facility
Counterparty
Hayfin Services LLP, as administrative agent, and the lenders parties thereto
Effective
2023-01-19
Exact text from the filing
On January 19, 2023, Xeris Biopharma Holdings, Inc. (the “Company”) entered into Amendment No. 2 to Credit Agreement and Guaranty (“Amendment No. 2”) with Xeris Pharmaceuticals, Inc. (“Xeris Pharma”), the lenders parties thereto (the “Lenders”) and Hayfin Services LLP, as administrative agent for the Lenders (in such capacity, together with its successors and assigns, the “Agent”), to amend that certain Credit Agreement and Guaranty, dated as of March 8, 2022, as amended by Amendment No. 1 to Credit Agreement and Guaranty dated September 29, 2022 (the “Credit Agreement”), by and among the Company, Xeris Pharma, the subsidiary guarantors from time to time parties thereto, the Agent and the Lenders from time to time parties thereto.
View on SEC.gov

38 material agreements filed in the last 30 days. Browse all material agreements →

Xeris Biopharma Holdings, Inc. filing history →

Source: SEC EDGAR
accession 0001867096-23-000006
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.